Boston Scientific’s spinal cord stimulation therapy wins NICE recommendation

In its final guidance, the National Institute for Health and Clinical Excellence (NICE) has confirmed that spinal cord stimulation (SCS) is both safe and clinically effective in these patients. Importantly, NICE has also concluded that SCS is cost-effective when used to treat patients with chronic neuropathic pain, despite the use of conservative modeling techniques in the appraisal.

The NICE appraisal reviewed the clinical data available for patients with either failed back surgery syndrome or complex regional pain syndrome. It concluded that the trial data provided solid clinical evidence that SCS is an effective treatment for neuropathic pain. As a result, NICE has formally recommended SCS as an effective treatment for adult patients in England and Wales who have suffered chronic pain of neuropathic origin for at least six months, despite conventional medical management.

The recommendation paves the way for better patient access to SCS therapy. The National Health Service in England and Wales is directed to provide funding and resources for NICE-approved technologies normally within three months of publication date.

David McFaul, Boston Scientific’s senior vice president, international, said: “Our Precision spinal cord stimulation system is rechargeable and combines breakthrough technology with features designed to enhance patient convenience. It allows pain specialists to offer cost-effective treatments for chronic pain and help improve the quality of patient care.”